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SERUM CONCENTRATIONS OF CATHEPSIN K IN PAGET’S DISEASE OF BONE
BEFORE AND AFTER BISPHOSPHONATES INTRAVENOUS TREATMENT
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R. Valenti, R. Nuti
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Cathepsin K is a cysteine protease enzyme with high expression in bone. It is synthesized by the resorb-
ing osteoclast, and regulates the degradation of the organic matrix of bone. It cleaves both helicoidal and
telopeptide regions of collagen type I. Importantly bone resorption is impaired in cathepsin K deficiency.
The aim of the present study was to evaluate serum cathepsin K levels in 60 patients affected with
Paget’s disease of bone (PDB) before and after treatment with different intravenous bisphosponates com-
pared to control age-matched women (n=30) and men (n=20). Circulating cathepsin K levels were deter-
mined by a specific sandwich enzyme immunoassay. The detection limit was 1.1 pmol/l, and the CV were
4-6%. Serum total alkaline phosphatase (ALP), crosslaps (sCTX) and bone-specific ALP (BALP) were al-
so measured. After recruitment, 28 of the 70 PDB patients were treated with intravenous pamidronate
and 12 with zoledronate with follow-up serum sampling at days 3, 30, 90 and 180 after each treatment.
Pre-treatment cathepsin K levels were significantly higher in PDB patients than controls. Moreover, in
PDB subjects baseline cathepsin K positively correlated with sCTX and urinary calcium but not with ALP
and BALP. Similar but weaker correlations were observed in controls. Overall, intravenous bisphospho-
nate treatment significantly reduced cathepsin K levels by 28%, 34%, 45% and 29% at respectively 3, 30,
90 and 180 days. The reduction at each time point was significantly higher in patients treated with zole-
dronic acid than in those treated with pamidronate. With pamidronate, a trend for an increase in cathepsin
K levels at 180 vs. 90 days of follow-up was observed. On the opposite, ALP and BALP levels significant-
ly decreased at 30, 90 and 180 days, without any significant increase between 90 and 180 days.   
Our data suggest that serum cathepsin K could be a valuable parameter in the evaluation of subjects with
PDB as well as in the follow up of different bisphosphonate treatments. The observed increase in cathep-
sin K levels with respect to ALP or BALP observed 180 days after pamidronate treatment may suggest a
better sensitivity of cathepsin K in predicting the recurrence in disease activity.
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